Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.90%168.391.3%$496.78m
BIIBBiogen Inc.
0.65%230.761.3%$480.84m
CELGCelgene Corporation
-0.62%94.831.3%$471.13m
GILDGilead Sciences, Inc.
-0.75%65.860.9%$453.88m
ILMNIllumina, Inc.
-2.29%300.593.5%$305.96m
REGNRegeneron Pharmaceuticals, Inc.
-0.78%302.572.6%$276.84m
AAgilent Technologies, Inc.
-0.29%68.911.6%$198.64m
VRTXVertex Pharmaceuticals Incorporated
-1.78%165.731.9%$176.80m
EXASExact Sciences Corporation
-0.16%96.0425.3%$171.72m
ALXNAlexion Pharmaceuticals, Inc.
-2.80%127.232.0%$150.06m
BMRNBioMarin Pharmaceutical Inc.
-2.31%86.664.3%$118.53m
SRPTSarepta Therapeutics, Inc.
-3.37%117.5714.7%$114.20m
INCYIncyte Corporation
-0.48%76.832.5%$105.26m
IONSIonis Pharmaceuticals, Inc.
0.09%67.468.2%$98.12m
ALNYAlnylam Pharmaceuticals, Inc
-2.49%65.869.2%$93.34m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.